$AMERICAN News

Last published 3mo ago

3mo agoEXOD AMERICANLithic and Monavate Partner to Power Card Programs Across Traditional and On-Chain FinanceBusiness WireLithic's processing platform and Monavate's regulated issuing and settlement give fintech and digital asset companies one path to launch and scale card programs Lithic, the card issuer processing platform
1y agoWWR AMERICANWestwater Resources Acknowledges Increase in Off-Take InterestBusiness WireWestwater Resources, Inc. (NYSE:AMERICAN), an energy technology and battery-grade natural graphite company ("Westwater" or the "Company"), is pleased to announce an increase in customer interest relating to off-take
1y agoWWR AMERICANWestwater Resources Successfully Commissions Kellyton Qualification LineBusiness WireCSPG qualification line commissioned in December 2024 Now capable of producing ~1mt per day of battery anode material Westwater Resources, Inc. (NYSE:AMERICAN), an energy technology and battery-grade natural
1y agoWWR AMERICANWestwater Resources Applauds the Recent Executive Orders Which Emphasize the Importance of Critical Minerals Such as Battery Grade GraphiteBusiness WireNational Energy Emergency Executive Order to unleash the mining and production of critical minerals Executive Order calling on EPA and Interior Department to scrap all agency actions which impose an ‘undue burden'
2y agoWWR AMERICANWestwater Resources Applauds Treasury Department Guidance on 45X Advanced Manufacturing Production CreditBusiness WireUpdated guidance allows for inclusion of raw material costs in the 10% production tax credit. Applies to both critical minerals and electrode active materials including anodes. Westwater Resources, Inc.
2y agoWWR AMERICANWestwater Resources Supports Office of the United States Trade Representative Decision to Implement Section 301 Tariffs on Natural GraphiteBusiness WireModified Section 301 tariffs will implement a new 25% tariff on natural graphite imports from China. Section 301 tariffs play a critical role in driving demand for U.S.-produced anode materials. Westwater
2y agoWWR AMERICANWestwater Resources Announces Off-Take Agreement for Sale of 100% of Fines Graphite Production from its Kellyton PlantBusiness WireWestwater contracts with Hiller Carbon, a leading supplier of materials to the steel and foundry industries, to supply 100% of its natural graphite Fines production. With this binding Off-Take Agreement and the
2y agoSSY AMERICANSunLink Health Systems, Inc. Announces Sale of Trace Extended Care & RehabBusiness WireSunLink Health Systems, Inc. (NYSE:AMERICAN) today announced that its subsidiary, Southern Health Corporation of Houston, Inc., has completed the sale of its Trace Extended Care & Rehab senior care facility and
2y agoVINE AMERICANFresh Vine Wine Inc Reaches Marketing Agreement with Splash Wines, Inc., the Highest Rated Direct-to-Consumer Digital Wine Company in the USAGlobeNewswireCHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fresh Vine Wine Inc (NYSE:AMERICAN) today announced that it has reached a marketing agreement with Splash Wines, Inc., the highest rated direct-to-consumer digital
2y agoWWR AMERICANWestwater Resources Announces First Off-Take Agreement for Sale of Graphite from its Kellyton PlantBusiness WireWestwater contracts to supply natural purified graphite anode material to SK On, a leading manufacturer of EV batteries, at its plants in the U.S. Off-Take Agreement a critical element to obtaining financing for
2y agoSSY AMERICANSunlink Health Systems' Subsidiary Reaches Revised Agreements for the Sale of Trace Regional Medical Center and ClinicsBusiness WireSunLink Health Systems, Inc. (NYSE:AMERICAN) today announced that its indirect subsidiary, Southern Health Corporation of Houston, Inc. ("Southern"), has reached a revised agreement for the sale of Trace Regional
2y agoOZ AMERICANBelpointe OZ Signs Greystar as Their Property Manager for Aster & Links, Two Luxury 10-story Buildings in Sarasota, FLGlobeNewswireGreenwich, CT, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Belpointe PREP, LLC (NYSE:AMERICAN) ("Belpointe OZ" or the "Company"), the first publicly traded Qualified Opportunity Fund ("QOF"), is pleased to announce the signing
2y agoSSY AMERICANSunLink Health Systems Reaches Agreement for Sale of Trace Regional Medical CenterBusiness WireSunLink Health Systems, Inc. (NYSE:AMERICAN) today announced that its subsidiary, Crown Healthcare Investments, LLC, has signed an agreement with Progressive Health Group, LLC ("Buyer") for the sale of the subsidiary
3y agoWWR AMERICANNew Chinese Restrictions on Supply of Natural Graphite Will Negatively Impact Batteries Used in EV MarketBusiness WireWestwater Resources Offers Domestic Alternatives Westwater Resources, Inc. (NYSE:AMERICAN), an energy technology and battery-grade natural graphite company ("Westwater Resources"), today acknowledged that new Chinese
3y agoWWR AMERICANWestwater Resources Executes Letter of Intent with Dainen Material, a Japanese Anode Supplier to Leading Japanese ManufacturersBusiness WireWestwater to source CSPG from its Kellyton advanced graphite processing plant Westwater Resources, Inc. (NYSE:AMERICAN), an energy technology and battery-grade natural graphite company ("Westwater Resources"), today
3y agoWWR AMERICANWestwater Resources Announces Joint Development Agreement with SK On, a Leading Electric Vehicle Battery ManufacturerBusiness WireWestwater to develop anode materials tailored for SK On battery plants in the U.S. Graphite anode materials to be produced at Westwater's Kellyton processing plant Westwater Resources, Inc. (NYSE:AMERICAN), an
4y agoAIM AMERICANAIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus DiseaseGlobeNewswireAmpligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system Ampligen
4y agoAIM AMERICANDelaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group's Nominations ValidBusiness WireCourt Denies Jonathan Jorgl's Request for Preliminary Injunction; Finds that Jorgl Failed to Show Director Nomination Notice Complied with AIM's Bylaws and that Evidence Suggests Notice was Misleading Activist Group
4y agoAIM AMERICANAIM ImmunoTech Board Issues Letter to ShareholdersBusiness WireCorrects the Record Regarding Activist Group's False and Misleading Statements Highlights Evidence of Group's Scheme to Have Jorgl Serve as the "Face of the Activist" to Help Them "Get Control" Without Paying a Premium
4y agoAIM AMERICANAIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID ConditionsGlobeNewswireOCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of
4y agoAIM AMERICANAIM ImmunoTech to Present at the Virtual Investor Long COVID EventGlobeNewswireOCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to ShareholdersBusiness WireHighlights Significant Progress Made in Recent Years – and Especially Over Past 18 Months – in Repurposing Lead Drug Ampligen in Oncology to Benefit Patients and All Shareholders Calls on Shareholders to Support Continued Positive Momentum by Re-
4y agoAIM AMERICANAIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireOCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and CareGlobeNewswireOCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant MelanomaGlobeNewswirePhase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA, Fla., Aug. 30, 2022 (GLOBE NEWSWIRE) -- AIM Imm
4y agoAIM AMERICANAIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic CancerGlobeNewswireCompany receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer OCALA, Fla., Aug.
4y agoAIM AMERICANAIM ImmunoTech Provides Update on Jorgl Activist Group LitigationBusiness WireAIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement
4y agoAIM AMERICANAIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and regulatory value-driving mileston
4y agoIOR AMERICANIncome Opportunity Realty Investors, Inc. Reports Earnings for Quarter Ended June 30, 2022Business WireIncome Opportunity Realty Investors, Inc. (NYSE:AMERICAN) is reporting its results of operations for the quarter ended June 30, 2022. For the three months ended June 30, 2022 and 2021, we reported net income attributable to common shares of $0.8 million
4y agoAIM AMERICANAIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVIDGlobeNewswireOCALA, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published dataGlobeNewswireAmpligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data provide further validation for adva
4y agoAIM AMERICANAIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are InvalidGlobeNewswireFiles Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and SEC and Florida Injunctions Co
4y agoAIM AMERICANAIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight SeriesGlobeNewswireOCALA, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vira
4y agoAIM AMERICANAIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and TestingGlobeNewswireOCALA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or PreventionGlobeNewswireOCALA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireOCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral
4y agoAIM AMERICANAIM ImmunoTech Provides Update on Ampligen Long COVID Development ProgramGlobeNewswireOCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vira
4y agoAIM AMERICANAIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast
4y agoAIM AMERICANAIM ImmunoTech to Participate in a Solve M.E. Signature Event: 'Long COVID: Research, Policy, and Economic Impact' on May 19, 2022GlobeNewswireOCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral
4y agoAIM AMERICANAIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade TherapiesGlobeNewswireAmpligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with checkpoint blockade therapies in human clinical st
4y agoAIM AMERICANAIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic CancerGlobeNewswire- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer - Company engages world-renowned CRO, Amarex Clinical Research LLC to conduct up
4y agoAIM AMERICANAIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the LiverGlobeNewswirePrimary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen may be useful to enhance effectiveness of immunotherapies Data from clinical research conducted at Ro
4y agoAIM AMERICANAIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast CancerGlobeNewswirePhase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint Positive data from this proof-of-concept study demonstrate that short-term sy
4y agoAIM AMERICANAIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen® in multiple high-value indications - Company expected to continue advancing oncology-focused p
4y agoAIM AMERICANAIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World CongressGlobeNewswireOCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual MeetingGlobeNewswireOCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-VestGlobeNewswireOCALA, Fla., March 23, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir
4y agoAIM AMERICANAIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic CancerGlobeNewswireData seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a single-center named patient program, treatment with Ampl
4y agoCEI AMERICANCamber Energy Redeems Preferred SharesACCESS NewswireHOUSTON, TX / ACCESSWIRE / March 11, 2022 / Camber Energy, Inc. (NYSE:AMERICAN) ("Camber" or the "Company") is pleased to announce that on March 10, 2022 it redeemed 2,636 shares of Series G Preferred Stock (the "Series G Shares"), which were previously
4y agoAIM AMERICANAIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual MeetingGlobeNewswireOCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir